The Global Pain Market, 2008-2023 : Market Research Report

The Global Pain Market, 2008-2023

Published by: Visiongain

Published: Nov. 13, 2008 - 102 Pages

1 Executive Summary: 1.1 The Pharmaceutical Pain Market Review: Entering a Crucial Period; 1.2 Aims, Scope and Format of the Report
2 Introduction to Pain: 2.1 What is Pain?; 2.2 Pain Pathways; 2.3 Classification and Types of Pain
3 An Overview of the Global Pain Pharmaceutical Market 2008-2023: 3.1 The Global Pain Pharmaceutical Market Analysis; 3.2 Major Success in the Pain Pharmaceutical Market Has Proved to Be Elusive to Date; 3.3 While the Past Has Been Difficult for Pain Management, There is Optimism for the Future
4 The Global Non-Narcotics Market 2008-2023: 4.1 Non-Narcotics Market Analysis; 4.2 Efferalgan Currently Leads the Non-Narcotics Market - But Will This Last?; 4.3 Tylenol Set to Reach Blockbuster Status; 4.4 Aspirin Bayer - Huge Amount of Line Extensions Keeping Sales Up; 4.5 Advil Set to Exhibit Strong Growth?; 4.6 Tramal - How Will Sales Develop?; 4.7 The Non-Narcotics Market Currently Dominates the Pain Industry
5 The Global Narcotics Market 2008-2023: 5.1 Narcotics Market Analysis; 5.2 Oxycontin - Beset by Major Challenges; 5.3 Duragesic; 5.4 Oxycodone TEVA; 5.5 Fentanyl MYLA - How Will Sales Develop?; 5.6 Fentanyl NOVT - How Will Sales Develop?; 5.7 Total Sales in the Narcotics Market Will Increase Despite Being Crowded
6 The Global Anti-Arthritic Market 2008-2023: 6.1 Anti-Arthritic Market Analysis; 6.2 Pfizer's Celebrex Dominates the Market, But Will This Last?; 6.3 Voltaren - How Will Sales Develop?; 6.4 Arcoxia Has Reduced Gastro Intestinal Effects; 6.5 Mobic Will Suffer from Generic Competition; 6.6 Arthrotec Will Decline in Growth; 6.6.1 Development of Arthrotec (Diclofenac/Misoprostol); 6.7 Rises Predicted for Global Arthritis Market
7 The Global Anti-Migraine Market 2008-2023: 7.1 Anti-Migraine Market Analysis; 7.2 GSK's Blockbuster Imitrex/Imigran - How Will Sales Develop?; 7.3 Merck & Co's Maxalt - The New Market Leader Perhaps?; 7.4 Zomig Shows Positive Growth; 7.5 Relpax - How Will Sales Develop?; 7.6 Naramig - How Will Sales Develop?; 7.7 What Does the Future Hold for Migraine Therapy?; 7.8 What are the Unmet Needs in the Management of Migraine
8 SWOT Analysis: 8.1 SWOT Analysis of the Global Pain Market; 8.2 Market Drivers; 8.3 Market Restraints; 8.4 The Pain Market Suffered After the Withdrawal of COX-2 Inhibitors; 8.5 Lack of Adequate Reimbursement Limits Potential of Pain Drugs; 8.6 Patients Dependent on Reformulations of Existing Drugs; 8.7 The Narcotics Market Suffers from Serious Side Effects; 8.8 The Under-Treatment of Pain; 8.9 How Might These Findings Affect the Market for Pain Drugs?; 8.10 The Future of the Pain Market - Closing Comments
9 Pipeline Products for the Treatment of Pain: 9.1 The Pipeline in the Pain Market is Large and Expanding; 9.2 The Potential of the Pain Market Has Encouraged R&D Efforts; 9.3 Innovation Rules for Early-Stage Pipeline Drugs; 9.4 Late-Stage Pipeline Products in the Non-Narcotics Market; 9.5 Late-Stage Pipeline Products in the Narcotics Market; 9.6 Late-Stage Pipeline Products in the Anti-Arthritic Market; 9.7 Late-Stage Pipeline Products in the Anti-Migraine Market; 9.8 The Pain Pipeline Shows Short- and Long-Term Potential
10 Future Therapies: 10.1 Cannabinoids and Pain: An Alternative to Opioids?; 10.2 Experimentally Induced Acute Pain; 10.3 Post Surgical Acute Pain; 10.4 Chronic Pain; 10.5 Sativex; 10.6 Cannabinoids and Pain: a Lucrative Market?; 10.7 The Future of Pain Research; 10.8 Advanced Drug Delivery
11 Conclusions: 11.1 The Pain Market is Heading for Consistent Financial Growth; 11.2 Will the Non-Narcotics Segment Dominate the Pain Market in Future?; 11.3 The Narcotics Market Will be Hampered by Controversial Issues; 11.4 The Anti-Arthritic Market Shows No Signs of Slowing Down; 11.5 The Anti-Migraine Market Will Suffer Due to Patent Expiry of Key Products; 11.6 Major Success in the Pain Pharmaceutical Market Has Proved to Be Elusive to Date; 11.7 Why Growth in the Pain Market Will Continue
List of Tables: Table 3.1 The Global Pain Pharmaceutical Market Forecast ($m), 2008-2023; Table 3.2 Revenues ($m), 6-Year CAGR (%) and Market Share (%) for the Leading Pain Markets, 2007 & 2013; Table 3.3 Top Ten Products in the Pain Market ($m), 2007; Table 4.1 The World Non-Narcotics Market ($m) Forecast 2008-2023; Table 5.1 The World Narcotics Market ($m) Forecast 2008-2023; Table 6.1 The World Anti-Arthritic Market ($m) Forecast 2008-2023; Table 7.1 The World Anti-Migraine Market ($m) Forecast 2008-2023; Table 8.1 A SWOT Chart for the Pain Market, 2008-2013; Table 9.1 Late-Stage Non-Narcotic Pipeline Drugs for Pain, 2008; Table 9.2 Late-Stage Narcotic Pipeline Drugs for Pain, 2008; Table 9.3 Late-Stage Anti-Arthritic Pipeline Drugs for Pain, 2008; Table 9.4 Late-Stage Anti-Migraine Pipeline Drugs for Pain, 2008
List of Figures: Figure 3.1 The Global Pain Pharmaceutical Market Revenue Forecast ($m), 2008-2023; Figure 3.2 Leading Pain Markets’ Revenue ($m) Comparison, 2007 & 2013; Figure 3.3 Leading Pain Sectors’ Market Share (%), 2007; Figure 3.4 Leading Pain Sectors’ Market Share (%), 2013; Figure 4.1 Non-Narcotics World Market Revenue Forecast ($m), 2008-2023; Figure 4.2 Efferalgan Revenue Forecast ($m), 2008-2023; Figure 4.3 Tylenol Revenue Forecast ($m), 2008-2023; Figure 4.4 Aspirin Bayer Revenue Forecast ($m), 2008-2023; Figure 4.5 Advil Revenue Forecast ($m), 2008-2023; Figure 4.6 Tramal Revenue Forecast ($m), 2008-2023; Figure 5.1 Narcotics World Market Revenue Forecast ($m), 2008-2023; Figure 5.2 Oxycontin Revenue Forecast ($m), 2008-2023; Figure 5.3 Duragesic Revenue Forecast ($m), 2008-2023; Figure 5.4 Oxycodone TEVA Revenue Forecast ($m), 2008-2023; Figure 5.5 Fentanyl MYLA Revenue Forecast ($m), 2008-2023; Figure 5.6 Fentanyl NOVT Revenue Forecast ($m), 2008-2023; Figure 6.1 Anti-Arthritic World Market Revenue Forecast ($m), 2008-2023; Figure 6.2 Celebrex Revenue Forecast ($m), 2008-2023; Figure 6.3 Voltaren Revenue Forecast ($m), 2008-2023; Figure 6.4 Arcoxia Revenue Forecast ($m), 2008-2023; Figure 6.5 Mobic Revenue Forecast ($m), 2008-2023; Figure 6.6 Arthrotec Revenue Forecast ($m), 2008-2023; Figure 7.1 Anti-Migraine World Market Revenue Forecast ($m), 2008-2023; Figure 7.2 Imitrex/Imigran Revenue Forecast ($m), 2008-2023; Figure 7.3 Maxalt Revenue Forecast ($m), 2008-2023; Figure 7.4 Zomig Revenue Forecast ($m), 2008-2023; Figure 7.5 Relpax Revenue Forecast ($m), 2008-2023; Figure 7.6 Naramig Revenue Forecast ($m), 2008-2023; Figure 11.1 The Global Pain Pharmaceutical Market Revenue Forecast ($m), 2008-2023
Companies listed:: AstraZeneca; Abbott; Acura; Alpharma; Anesiva; Astellas; Bayer; Biovail; Bristol Myers Squibb; Daiichi Sankyo; Dr. Reddy’s Laboratories; Eisai; Ethypharm; Gruenenthal; GSK; GW pharmaceuticals; Horizon; Idea; Javelin; Johns Hopkins University; Johnson & Johnson; Kowa; Labopharm; MAP Pharmaceuticals; Meda; Merck & Co; NicOx; Novartis; Ono; Pacira Pharmaceuticals; Pain Therapeutics; Paion; Pfizer; PLx Pharma; Pozen; Purdue Pharma; QRxPharma; Ranbaxy; Recordati; Roxro; Shionogi; Symbollon; Teva; UCB; Wex; Winston Laboratories; Zogenix

Abstract

The global pain market generated total sales of $34bn in 2007 - but what will the figures be in the next 5 and 10 years? This report tells you.

The pain market has marked strengths and advantages, but is also limited by problems and concerns. The market will be driven by new drugs and reformulations of existing ones - but which drugs will be most successful? The incidence of pain is increasing rapidly, what some experts call a pain epidemic - so the opportunities available to an additional blockbuster drug is significant. The prevention and treatment of pain is already one of the highest priorities for healthcare authorities in the world, yet for mature markets pain drug sales have fallen. However, visiongain believes that this market has strong growth potential, despite the prospect of generic competition for leading branded products.

The pain market contained four blockbuster drugs in 2007. Visiongain predicts that there will be room for more blockbuster drugs in that market segment during the years ahead as new products are launched, replacing older products. There is great potential for treatments with greater safety, efficacy and tolerability. This report - The Global Pain Market, 2008-2023 - provides analysis and forecasts for the overall pain market and its principal subdivisions, as well as for leading products within those categories. This study also highlights promising pipeline developments and important contemporary issues, especially commercial drivers and restraints.

In particular, The Global Pain Market, 2008-2023 analyses global markets for the following groups of pain treatment:

Non-narcotics
Narcotics
Anti-arthritic treatments
Anti-migraine treatments.

This report delivers:

Key analysis split by region and class
Future market analysis right through to 2023
Analysis of key brands, generics, strategies in-place today and future strategies over the next 15 years
Analysis of key players in the pain market, current and future licensing strategies

This report examines the global pain drug market critically through a comprehensive review of available information. Sources used include internal databases, industrial databases, commercial news, company reports, published reports and economic research. Visiongain applies in-house financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.

In particular, The Global Pain Market, 2008-2023 concentrates on the following essential aspects of the market:

Forecast for the worldwide pain pharmaceutical market from 2008 to 2023
Forecasts for the principal submarkets from 2008 to 2023
Commercial prospects for the market-leading drugs, with sales forecasts from 2008 to 2023
Drivers and restraints in the pain market
Opportunities and threats in the pain market
Future therapies that will drive growth in this market
Pipeline developments with significant commercial potential
Currently marketed drugs with blockbuster potential
Discussion of unmet therapeutic needs and relative advantages of products.

Why you should buy this report:

To receive a comprehensive analysis of the prospects for pain drugs from 2008 to 2023
To discover predicted revenues, growth rates and other key metrics for leading pain treatments from 2008 to 2023
To discover “hot” pipeline developments and up-and-coming products
To determine the forces that influence the market for pain drugs:
Competitive characteristics of the market
Drivers
Restraints
Strengths, weaknesses, opportunities and threats in that market
To find out where the market is heading - both technologically and commercially - from 2008 onwards.

Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

The Global Pain Market, 2008-2023

Table of Contents

Abstract